Newron Pharmaceuticals SpA (NP5.DE)

3.54 €

+0.39 (+12.38%)
Rating:
Recommendation:
-
Symbol NP5.DE
Price 3.54 €
Beta 2.153
Volume Avg. 0.00M
Market Cap 0.000M
Shares () -
52 Week Range 1.13-3.54
1y Target Est -
DCF Unlevered NP5.DE DCF ->
DCF Levered NP5.DE LDCF ->
ROE -317.88% Strong Sell
ROA -43.44% Strong Sell
Operating Margin -
Debt / Equity -930.18% Strong Sell
P/E -
P/B -12.04 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Prof. Stefan Weber
Pharmaceuticals
Pharmaceuticals, Biotechnology & Life Sciences
XETRA

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 24 full-time employees. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.